|Last||Change / % Change||Dividend Yield||Volume||Avg Volume (10 day)|
Market data is delayed by at least 20 minutes.
Latest News Headlines for Biogen Idec Inc
Biogen Idec Appoints Spyros Artavanis-Tsakonas Chief Scientific Officer
-- Addition of Renowned Scientist Underscores Commitment to Vibrant and Innovative Scientific Research -- WESTON, Mass.--(BUSINESS WIRE)--May 23, 2013-- Biogen Idec (NASDAQ:BIIB) today announced that Spyros Artavanis-Tsakonas, Ph.D., has been named the company's Chief Scientific Officer (CSO). Dr. Artavanis-Tsakonas had served as interim CSO while on sabbatical from Harvard Medical School. He will now continue in this role in a permanent capacity, and will also lead the company's research strategy, capabilities and discovery platforms. Dr. Artavanis-Tsakonas will report to Doug Williams, Executive Vice President of Research and Development. He will continue to serve as a Professor of Cell Biology at Harvard Medical School, where he was the founding Director of the Developmental and Regenerative Biology graduate program.
Biogen Idec to Present at the Deutsche Bank 38th Annual dbAccess Healthcare Conference
WESTON, Mass.--(BUSINESS WIRE)--May 22, 2013-- Biogen Idec Inc. (NASDAQ: BIIB) announced today that it will present at the Deutsche Bank 38th Annual dbAccess Healthcare Conference. The webcast will be live on Thursday, May 30, 2013 at 12:00 p.m. ET. To access the live webcast, please visit Biogen Idec's Investors section at www.biogenidec.com. An archived version of the webcast will be available for 14 days following the presentation.
Biogen Idec Submits Application to FDA for Approval of PLEGRIDY(TM) (Peginterferon Beta-1a) in Multiple SclerosisView more recent headlines
-- EMA Submission Planned in the Coming Weeks -- WESTON, Mass.--(BUSINESS WIRE)--May 21, 2013-- Today Biogen Idec (NASDAQ: BIIB) announced it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval of PLEGRIDY(TM) (peginterferon beta-1a), the company's pegylated subcutaneous injectable candidate for relapsing forms of multiple sclerosis (RMS).
Latest Annual and Quarterly SEC Filings
Biogen Idec Inc. (Biogen Idec) is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The Company's products include AVONEX, TYSABRI, FAMPYRA, FUMADERM and RITUXAN. In September 2011, the Company acquired from the Dompe Group the noncontrolling interests in its joint venture sales affiliates in Italy and Switzerland. In April 2013, Elan Corporation, plc closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.
-- / --
-- / --
238.83 / 5/22/2013
126.39 / 6/4/2012
% off 52wk High
% off 52wk Low
Beta (5 Yr)
Date of Record
0.00 - --
Last Trade as of 5/24/2013 4:00 PM ET